1
项与 人凝血酶原复合物(LFB Biotechnologies SASU) 相关的临床试验Phase 3 Study Comparing Preventive Reversal of Vitamine K Antagonist Versus Reversion Only in Case of Intracranial Bleeding in Patients Receiving Vitamine K Antagonist Treatment
The occurence of a minor craniocerebral trauma in patients receiving vitamine K antagonist treatment leads to a high risk of bleeding.
Current guidelines recommend to perform a CT scan, and, in case of intracranial bleeding, to reverse anticoagulation with concomitant administration of prothrombin complex concentrates (PCCs) and vitamin K.
However, even if a reversion is performed, the prognostic of post-traumatic intracranial bleeding remain bad.
The investigators hypothesize that, for patients admitted in an emergency department after a minor head trauma and receiving anticoagulant treatment, a systematic preventive reversion with PCCs can lead to a significant reduction of intracranial haemorrhage and can also improve the neurological prognostic of patients versus the current strategy.
PREVACT will test this hypothesis, in an open label, randomized, multicentre, clinical trial involving 400 patients.
100 项与 人凝血酶原复合物(LFB Biotechnologies SASU) 相关的临床结果
100 项与 人凝血酶原复合物(LFB Biotechnologies SASU) 相关的转化医学
100 项与 人凝血酶原复合物(LFB Biotechnologies SASU) 相关的专利(医药)
100 项与 人凝血酶原复合物(LFB Biotechnologies SASU) 相关的药物交易